Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea–(BUSINESS WIRE)–#ADC–Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by … [Read more…]
IRVINE, Calif.–(BUSINESS WIRE)–Advanced Sterilization Products (ASP), a global leader in infection prevention and low‑temperature sterilization, today announced a strategic partnership with ChemDAQ, a leading provider of hazardous gas detection and monitoring solutions. Together, ASP and ChemDAQ will support healthcare organizations by strengthening safety practices, reinforcing regulatory confidence, and advancing best‑in‑class sterile processing environments. As part … [Read more…]
Thursday, April 23, 10:00 AM EDT Miami, USA, via Zoom MIAMI–(BUSINESS WIRE)–#COVID–AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Will Equity Prevail? The PABS Annex Negotiations at Their Final Hour,” on Thursday, April 23, 2026 at 10:00 AM EDT, virtually via Zoom. Register here. … [Read more…]
In 2025, the Foundation directed nearly $6.4 million in philanthropic investments through grants, employee giving and matching contributions. PORTLAND, Ore.–(BUSINESS WIRE)–Cambia Health Foundation released its 2025 Community Impact Report, highlighting purposeful philanthropic funding to advance whole-person health and the dedication Cambia employees demonstrated through volunteerism and monetary giving. The Foundation’s strategic investments aim to expand … [Read more…]
RMA Basking Ridge (#8 Overall, #1 in NJ), Boston IVF Waltham (#11 Overall, #2 in MA), Conceptions RMA Colorado (#2 in CO), Ohio Reproductive Medicine (#2 in OH), UNC Fertility (#2 in NC) and others included on list of top 140 U.S. clinics BASKING RIDGE, N.J.–(BUSINESS WIRE)–IVI RMA North America, a leader in fertility care … [Read more…]
DMX-1001 (oral noribogaine) is a novel neuroplastogen therapeutic that combines neuroplasticity and polypharmacology for the treatment of AUD AUD affects more than 29 million Americans and is a leading cause of preventable death; about 60 percent of patients treated for AUD relapse to hazardous drinking within six months Successful completion of the planned alcohol interaction … [Read more…]
The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences’ development and manufacturing capabilities with Amneal Pharmaceuticals’ commercial strengths Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines PISCATAWAY, N.J.–(BUSINESS WIRE)–Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be … [Read more…]
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027 Drug candidate, a monoclonal antibody which targets S100A4, a novel upstream pathway implicated in fibrotic disease, aims to preserve lung function in IPF patients OSLO, Norway & … [Read more…]
New Clinic Brings Advanced Scoliosis and Hyperkyphosis Care to the Local Community BISMARCK, N.D.–(BUSINESS WIRE)–People across North Dakota now have greater access to specialized, non-surgical scoliosis and hyperkyphosis care following the opening of ScoliCare North Dakota. This new clinic delivers a patient-centered approach to scoliosis management, combining advanced technology with expert clinical care to improve … [Read more…]
STK-012 + pembrolizumab + chemotherapy in first‑line non‑squamous NSCLC demonstrated a 50% ORR in predominantly PD‑L1-negative patients 61% ORR with the regimen in patients with at least one mutation in the STK11, KEAP1, or SMARCA4 tumor suppressor genes 50% ORR, PFS 5.5 months, and 88% 6-month OS with the regimen in patients with STK11/KEAP1 co‑mutated … [Read more…]
